Skip to main content
SpringerLink
Log in

Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

This study was designed to evaluate the prevalence of chromosomal abnormalities and to identify the specific abnormalities associated with poor prognosis. A total of 2,474 patients whose conventional cytogenetics were available at the time of diagnosis were evaluated via a nationwide registry. Normal metaphase cytogenetics was observed in 2,012 patients (81.3%). Among the 462 patients with chromosomal abnormalities, there were 161 (34.8%) patients with hyperdiploidy, 197 (42.6%) with pseudodiploidy, 79 (17.1%) with hypodiploidy, and 25 (5.5%) with near-tetraploidy. Deletion 13 (Δ13) in metaphase was observed in 167 patients (6.8%). Fluorescent in situ hybridization (FISH) was carried out in 967 patients (39.1%), and 66 (13.7%) out of 482 and 63 (10.3%) out of 611 patients were positive for t(4;14) and del(17p), respectively. With a median follow-up duration of 25.1 months, the median overall survival (OS) was 51.2 months (95% confidence interval, 46.5–55.9 months). In univariate analysis, the following four chromosomal abnormalities were significantly associated with a poor survival outcome: Δ13, hypodiploidy, del(13q) in FISH, and del(17p) in FISH. In the subsequent multivariate analysis, in which del(13q) and del(17p) in FISH were excluded due to a relatively low number of patients, Δ13 and hypodiploid status were independently associated with a poor survival outcome after adjusting for important clinical factors, including age, sex, performance, beta2-microglobulin, albumin, and lactate dehydrogenase (LDH). Using conventional metaphase cytogenetics, we confirmed that both Δ13 and hypodiploid status were robust poor prognostic factors. The metaphase karyotyping should remain the primary cytogenetic tool and an essential investigation for risk stratification in newly diagnosed multiple myeloma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860–1873. doi:10.1056/NEJMra041875

    Article  CAS  PubMed  Google Scholar 

  2. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R (2007) A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 21(3):529–534. doi:10.1038/sj.leu.2404516

    Article  CAS  PubMed  Google Scholar 

  3. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23(12):2210–2221. doi:10.1038/leu.2009.174

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G (2011) Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med 269(2):137–147. doi:10.1111/j.1365-2796.2010.02324.x

    Article  CAS  PubMed  Google Scholar 

  5. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17(2):427–436. doi:10.1038/sj.leu.2402797

    Article  CAS  PubMed  Google Scholar 

  6. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575. doi:10.1182/blood-2002-10-3017

    Article  CAS  PubMed  Google Scholar 

  7. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109(8):3489–3495. doi:10.1182/blood-2006-08-040410

    Article  CAS  PubMed  Google Scholar 

  8. Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa A-M, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P (2012) Long-Term Analysis of the IFM 99 Trials for Myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 30(16):1949–1952. doi:10.1200/jco.2011.36.5726

    Article  PubMed  Google Scholar 

  9. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420. doi:10.1200/JCO.2005.04.242

    Article  PubMed  Google Scholar 

  10. Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M (2012) Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. Int J Hematol 95(5):516–526. doi:10.1007/s12185-012-1035-8

    Article  CAS  PubMed  Google Scholar 

  11. Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CJ, Yoo SJ, Kim HC, Chun HG, Min HC, Oh BR, Kim TY, Lee JH, Lee DS (2006) Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet 168(2):124–132. doi:10.1016/j.cancergencyto.2006.02.015

    Article  CAS  PubMed  Google Scholar 

  12. Inamoto Y, Kurahashi S, Imahashi N, Fukushima N, Adachi T, Kinoshita T, Tsushita K, Miyamura K, Naoe T, Sugiura I (2009) Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Am J Hematol 84(5):283–286. doi:10.1002/ajh.21390

    Article  PubMed  Google Scholar 

  13. Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH (2009) Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-dased data from the Korean Myeloma Registry. Acta Haematol 122(4):200–210

    Article  PubMed  Google Scholar 

  14. Comings DE, Avelino E, Okada TA, Wyandt HE (1973) The mechanism of C- and G-banding of chromosomes. Exp Cell Res 77(1):469–483

    Article  CAS  PubMed  Google Scholar 

  15. Shaffer LG, Slovak ML, Campbell LJ, eds. (2009) ISCN; an international system for human cytogenetic nomenclature. S Karger; Basel, Switzerland

  16. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G (2002) Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118(4):1041–1047

    Article  CAS  PubMed  Google Scholar 

  17. Stewart AK, Fonseca R (2005) Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23(26):6339–6344. doi:10.1200/JCO.2005.05.023

    Article  CAS  PubMed  Google Scholar 

  18. Kaufmann H, Krömer E, Nösslinger T, Weltermann A, Ackermann J, Reisner R, Bernhart M, Drach J (2003) Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol 71(3):179–183. doi:10.1034/j.1600-0609.2003.00111.x

    Article  CAS  PubMed  Google Scholar 

  19. Dewald GW, Therneau T, Larson D, Lee YK, Fink S, Smoley S, Paternoster S, Adeyinka A, Ketterling R, Van Dyke DL, Fonseca R, Kyle R (2005) Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106(10):3553–3558. doi:10.1182/blood-2005-05-1981

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B (2003) Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 120(1):44–52

    Article  PubMed  Google Scholar 

  21. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21(1):151–157. doi:10.1038/sj.leu.2404442

    Article  CAS  PubMed  Google Scholar 

  22. Li Q, An G, Li CW, Xu Y, Deng SH, Liu XP, Qi JY, Wang YF, Zou DH, Zhao YZ, Qiu LG (2011) The significances of 13q14 deletion for development and prognosis of multiple myeloma. Chin J Hematol [Zhonghua Xue Ye Xue Za Zhi] 32(4):217–220

    Google Scholar 

  23. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, Grange MJ, Monconduit M, Bastard C (1998) Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12(6):960–969

    Article  CAS  PubMed  Google Scholar 

  24. Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87(7):515–526. doi:10.1007/s00277-008-0483-y

    Article  PubMed Central  PubMed  Google Scholar 

  25. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ, Dastugue N, Schrappe M, Pui C-H, Basso G, Silverman LB, Janka-Schaub GE (2007) Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110(4):1112–1115. doi:10.1182/blood-2006-07-038299

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Muller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95(7):1150–1157. doi:10.3324/haematol.2009.016436

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL (2009) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 84(12):1095–1110. doi:10.4065/mcp.2009.0603

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96(4):1505–1511

    CAS  PubMed  Google Scholar 

  29. Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O’Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NEU, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277. doi:10.3324/haematol.2011.056176

    Article  PubMed Central  PubMed  Google Scholar 

  30. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa A-M, Sotto J-J, Wetterwald M, Dumontet C, Fuzibet J-G, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau J-L, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. doi:10.1182/blood-2006-08-040410

    Google Scholar 

  31. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ, Van Wier SA, Ahmann GJ, Fonseca R (2005) Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106(8):2837–2840. doi:10.1182/blood-2005-04-1411

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau J-L, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H, 2 obotIMWCP (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700. doi:10.1182/blood-2010-10-300970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea

    Sukjoong Oh & Dong Hoe Koo

  2. Department of Laboratory medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea

    Min-Jung Kwon

  3. Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea

    Kihyun Kim

  4. Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, South Korea

    Cheolwon Suh

  5. Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, South Korea

    Chang-Ki Min

  6. Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Sung-Soo Yoon

  7. Department of Hematology/Oncology, Pusan National University Hospital, Busan, South Korea

    Ho-Jin Shin

  8. Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea

    Deog-Yeon Jo

  9. Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea

    Jae-Yong Kwak

  10. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

    Jin Seok Kim

  11. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea

    Sang Kyun Sohn

  12. Department of Internal Medicine, Haeundae Paik Hospital, Inje University, Busan, South Korea

    Young-Don Joo

  13. Hematology-Oncology Clinic, National Cancer Center, Goyang-si, South Korea

    Hyeon-Seok Eom

  14. Department of Internal Medicine, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea

    Sung-Hyun Kim

  15. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea

    Yang Soo Kim

  16. Comprehensive Cancer Center, Inha University Hospital, Incheon, South Korea

    ChulSoo Kim

  17. Department of Internal Medicine, Ewha Woman’s University School of Medicine, Seoul, South Korea

    Yeung-Chul Mun

  18. Department of Internal Medicine, Ulsan University Hospital, Ulsan, South Korea

    Hawk Kim

  19. Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, South Korea

    Dong Soon Lee

  20. Department of Internal Medicine, Gachon University Gil Hospital, 1198 Guwol-dong, Namdong-gu, Incheon, 405-220, South Korea

    Jae Hoon Lee

Authors
  1. Sukjoong Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Hoe Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Min-Jung Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kihyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cheolwon Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chang-Ki Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sung-Soo Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ho-Jin Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Deog-Yeon Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jae-Yong Kwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jin Seok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sang Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Young-Don Joo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hyeon-Seok Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sung-Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yang Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. ChulSoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Yeung-Chul Mun
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Hawk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Dong Soon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Jae Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Korean Multiple Myeloma Working Party (KMMWP)

Corresponding author

Correspondence to Jae Hoon Lee.

Additional information

S. Oh and D.H. Koo contributed equally to this work as first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oh, S., Koo, D.H., Kwon, MJ. et al. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Ann Hematol 93, 1353–1361 (2014). https://doi.org/10.1007/s00277-014-2057-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2057-5

Keywords

Search

Navigation